Praxis Precision Medicines: Promising Epilepsy Portfolio Advances Justify Buy Rating
I'm PortAI, I can summarize articles.
JonesTrading analyst Justin Walsh reiterates a Buy rating on Praxis Precision Medicines due to promising epilepsy portfolio advancements. The EMBOLD trial of relutrigine showed significant efficacy, leading to early termination, while the RADIANT trial for vormatrigine indicated potential as a top antiseizure medication. Guggenheim also maintains a Buy rating with a $760 price target, highlighting strong potential for Praxis's assets to benefit patients.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments